Monopar Therapeutics financial data

Symbol
MNPR on Nasdaq
Location
1000 Skokie Blvd Suite 350, Wilmette, IL
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 416 % -44.5%
Debt-to-equity 5.75 % -76.3%
Return On Equity -41.8 % +62.2%
Return On Assets -39.5 % +55.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.17M shares -64.9%
Common Stock, Shares, Outstanding 6.13M shares -65.2%
Entity Public Float 6.41M USD +39.2%
Common Stock, Value, Issued 6.13K USD -65.2%
Weighted Average Number of Shares Outstanding, Basic 7M shares +99.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 14.3M USD +221%
General and Administrative Expense 4.82M USD +58.6%
Operating Income (Loss) -19.1M USD -155%
Net Income (Loss) Attributable to Parent -17.3M USD -143%
Earnings Per Share, Basic -3 USD/shares -4.07%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 39.5M USD +545%
Cash, Cash Equivalents, and Short-term Investments 10.4M USD
Other Assets, Current 497K USD +715%
Assets, Current 53.7M USD +649%
Operating Lease, Right-of-Use Asset 118K USD
Assets 53.9M USD +650%
Liabilities, Current 1.58M USD
Operating Lease, Liability, Noncurrent 80.4K USD
Liabilities 1.66M USD +52.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 77.6K USD +839%
Retained Earnings (Accumulated Deficit) -80.9M USD -27.2%
Stockholders' Equity Attributable to Parent 52.2M USD +757%
Liabilities and Equity 53.9M USD +650%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.66M USD -242%
Net Cash Provided by (Used in) Financing Activities -116K USD -104%
Net Cash Provided by (Used in) Investing Activities -326K USD +66.9%
Common Stock, Shares Authorized 40M shares 0%
Common Stock, Shares, Issued 6.13M shares -65.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.1M USD -1227%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.73M USD -67.9%
Deferred Tax Assets, Valuation Allowance 17.9M USD +34.7%
Deferred Tax Assets, Gross 17.9M USD +34.7%
Operating Lease, Liability 114K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -17.2M USD -141%
Lessee, Operating Lease, Liability, to be Paid 124K USD
Operating Lease, Liability, Current 33.4K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 43K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 43.8K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 10.4K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 10.7K USD
Deferred Tax Assets, Operating Loss Carryforwards 4.48M USD +15.6%
Unrecognized Tax Benefits 412K USD +22.6%
Additional Paid in Capital 63.1M USD +4.01%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 476K USD -4.72%